8-K: Boundless Bio Announces $14.5 Million At-the-Market Offering

Boundless Bio has entered into an agreement with Jefferies LLC to sell up to $14.5 million of its common stock through an at-the-market offering.

Summary

• Boundless Bio, Inc. has entered into an Open Market Sale Agreement with Jefferies LLC, effective April 1, 2025.
• Under the agreement, the company may sell shares of its common stock, with an aggregate offering price of up to $14.5 million, through at-the-market offerings.
• Sales will be made at prevailing market prices at the time of sale, or as otherwise agreed with Jefferies LLC.
• Jefferies LLC will receive a commission of up to 3.0% of the gross proceeds from the shares sold.
• The company is not obligated to sell any shares, and Jefferies LLC is not obligated to buy or sell any shares.
• The company has agreed to indemnify Jefferies LLC against certain liabilities.
• Both the company and Jefferies LLC can terminate the agreement with prior written notice.
• The shares will be issued under the company's shelf registration statement on Form S-3, filed with the SEC on April 1, 2025.
• The company has filed a legal opinion from Latham & Watkins LLP regarding the validity of the shares.

Sentiment

Score: 5

Explanation: The announcement is neutral. It's a standard capital-raising activity, but it could indicate the company needs more funds for operations or research.

Positives

• The agreement provides Boundless Bio with a flexible mechanism to raise capital.
• The at-the-market offering allows the company to sell shares at prevailing market prices.

Negatives

• The company will incur commissions of up to 3.0% on the gross proceeds of any shares sold.
• There is no guarantee that the company will be able to sell all or any of the shares.

Risks

• The market price of the company's common stock could be negatively impacted by the sale of shares.
• The company's ability to raise capital through this offering is subject to market conditions.
• The company may not be able to sell the shares at favorable prices.

Future Outlook

The company may sell shares of common stock from time to time, but there is no assurance as to the price or amount of shares that will be sold.

Industry Context

At-the-market offerings are a common way for biotech companies to raise capital, especially when they need flexibility and don't want to commit to a large, fixed-price offering.

Comparison to Industry Standards

• Many small to mid-cap biotech companies use ATM offerings to raise capital, similar to companies like XOMA Corporation and Catalyst Biosciences.
• The 3% commission is within the typical range for ATM offerings in the biotech industry.

Stakeholder Impact

• Shareholders may experience dilution if the company sells a significant number of shares.
• The capital raised could benefit the company's operations and research, potentially leading to long-term value creation.

Next Steps

• The SEC needs to declare the Registration Statement effective.
• The company may choose to sell shares of common stock from time to time through Jefferies LLC.

Key Dates

Keywords

at-the-market offering, common stock, Jefferies LLC, capital raise, Boundless Bio, Sales Agreement